US Broker Ratings

Embecta Corp. (EMBC) Stock Analysis: Navigating a 59% Potential Upside Amid Healthcare Innovations

Embecta Corp. (NASDAQ: EMBC), a prominent player in the healthcare sector, specifically within the Medical Instruments & Supplies industry, is poised for an intriguing journey. With its headquarters in Parsippany,..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: A 13.31% Upside with Strong Buy Ratings

Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a key player in the specialty pharmaceutical sector, focuses on developing and commercializing innovative pain management solutions. With a market capitalization of $1.48 billion, it..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring an 88.45% Potential Upside

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is emerging as a compelling player in the biotechnology sector, capturing the attention of investors with its promising pipeline and significant market potential. With a..

Theravance Biopharma Inc. (TBPH) Stock Analysis: Unveiling a 36% Potential Upside

Theravance Biopharma, Inc. (NASDAQ: TBPH) stands out in the biotechnology sector with its promising product pipeline and strategic collaborations. With a market capitalization of $992.17 million, Theravance is a key..

iRadimed Corporation (IRMD): Investor Outlook Reveals Nearly 5% Upside Potential

iRadimed Corporation (NASDAQ: IRMD) has been making waves in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $1.2 billion, the U.S.-based company is a..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking a 78% Potential Upside Amid Healthcare Innovations

Investors keen on the healthcare sector might find Relay Therapeutics, Inc. (NASDAQ: RLAY) a compelling story, given its significant potential upside and innovative approach in biotechnology. With a market capitalization..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Healthcare Star with a 208% Potential Upside

Niagen Bioscience, Inc. (NAGE), a prominent player in the biotechnology sector, is attracting significant attention with its compelling investment potential. Headquartered in Los Angeles, California, Niagen is dedicated to developing..

Enhabit, Inc. (EHAB) Stock Analysis: Unlocking a 6.62% Potential Upside in the Healthcare Sector

Enhabit, Inc. (EHAB), a significant player in the healthcare sector, has caught the attention of investors looking to capitalize on the growing demand for medical care facilities. With a current..

Enliven Therapeutics, Inc. (ELVN): Investor Outlook with a 53.3% Potential Upside and Strong Buy Ratings

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is capturing the attention of savvy investors in the biotechnology sector. With a market capitalization of $1.6 billion, this clinical-stage biopharmaceutical company is making waves..

Zymeworks Inc. (ZYME) Stock Analysis: Biotech’s 61.74% Upside Potential Amid Robust Revenue Growth

Investors eyeing opportunities in the biotechnology sector should take a closer look at Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage company making strides in the realm of cancer and autoimmune disease..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A 145% Upside Amidst Innovative Biotech Ventures

Sana Biotechnology, Inc. (NASDAQ: SANA) is capturing significant interest in the biotechnology sector, with a compelling potential upside of 145.47% based on current analyst targets. This Seattle-based company is carving..

Orthofix Medical Inc. (OFIX) Investor Outlook: Analyzing a Potential 53% Upside in the Medical Device Sector

Orthofix Medical Inc. (NASDAQ: OFIX), a prominent player in the healthcare sector specializing in medical devices, presents a compelling case for investors seeking opportunities in a challenging market. With a..

HealthStream, Inc. (HSTM) Stock Analysis: Unlocking a 60% Upside Potential

HealthStream, Inc. (NASDAQ: HSTM), a leading provider in the health information services sector, offers an intriguing investment opportunity as it stands poised for significant growth. With a current market capitalization..

Replimune Group, Inc. (REPL) Stock Analysis: Exploring an 85% Potential Upside in the Biotech Sector

Investors eyeing the biotechnology sector for promising opportunities might find Replimune Group, Inc. (NASDAQ: REPL) a compelling case, especially given its impressive potential upside of 85.53% based on current analyst..

Owens & Minor, Inc. (OMI) Stock Analysis: Exploring a 94% Potential Upside in the Healthcare Sector

Owens & Minor, Inc. (OMI), a key player in the healthcare sector, is drawing attention from investors due to its significant upside potential, pegged at 94.29%. This notable figure is..

Cogent Biosciences, Inc. (COGT) Investor Outlook: 42% Potential Upside Drives Interest in Biotech Innovator

Investors with an eye on the biotechnology sector may find Cogent Biosciences, Inc. (NASDAQ: COGT) a compelling opportunity. With a market capitalization of $5.48 billion, this American biotech company is..

CorMedix Inc. (CRMD) Stock Analysis: A Biotech Company with Over 100% Potential Upside

Investors seeking opportunities in the biotechnology sector might find CorMedix Inc. (NASDAQ: CRMD) an intriguing candidate. With a current market capitalization of $579.1 million, this healthcare sector player is gaining..

GH Research PLC (GHRS) Stock Analysis: A Biotech Pioneer with a 146.95% Upside Potential

GH Research PLC (NASDAQ: GHRS), an emerging player in the biotechnology sector, has garnered significant attention from the investment community, primarily due to its promising drug pipeline and substantial upside..

Delcath Systems, Inc. (DCTH) Investor Outlook: Analyzing a 149.81% Potential Upside in the Healthcare Sector

Delcath Systems, Inc. (NASDAQ: DCTH), a prominent player in the healthcare sector specializing in medical devices, is capturing investor attention with its robust potential upside of 149.81%. Situated at the..

Stoke Therapeutics, Inc. (STOK) Stock Analysis: Exploring a 37% Upside Potential

Stoke Therapeutics, Inc. (NASDAQ: STOK) has captured the attention of investors with its distinctive approach to treating severe genetic diseases. As a pioneering entity in the biotechnology sector, Stoke Therapeutics..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds